Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion

Technology appraisal guidance
Reference number: TA283
Published: 22 May 2013
Last updated: 20 May 2024

Macular oedema (retinal vein occlusion) - ranibizumab: comments on the DSU Report

Macular oedema (retinal vein occlusion) - ranibizumab: Novartis DSU comments
Macular oedema (retinal vein occlusion) - ranibizumab: Macular Disease Society DSU comments
Macular oedema (retinal vein occlusion) - ranibizumab: RNIB DSU comments
Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Nursing DSU comments
Macular oedema (retinal vein occlusion) - ranibizumab: Royal College of Ophthalmologists DSU comments
Macular oedema (retinal vein occlusion) - ranibizumab: NHS Wiltshire DSU comments
Macular oedema (retinal vein occlusion) - ranibizumab: Commissioning Support Appraisals Service DSU comments
Macular oedema (retinal vein occlusion) - ranibizumab: Allergan DSU comments
Macular oedema (retinal vein occlusion) - ranibizumab: Roche DSU comments

This page was last updated: 10 April 2013